Cartesian Therapeutics, Inc.
RNAC
Ранг среди акций
#18149
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Цена акции
$6.44
Последняя синхронизация: 2026-10-21
Рыночная капитализация
$194.84M
Изменение (1 день)
0.70%
Изменение (1 год)
865.08%
Страна
US
Торговля Cartesian Therapeutics, Inc. (RNAC)
Категория
Healthcare
История цены акций Cartesian Therapeutics, Inc. (RNAC)
Наивысшая цена закрытия: $0.79 2023-12-01
Наименьшая цена закрытия: $14.00 2016-06-01
Наименьшая цена закрытия: $14.00 2016-06-01
История цены акций Cartesian Therapeutics, Inc. с 2016 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
